Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 4 1Phase 1 1

Status

Completed 5Unknown 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

anlotinib 5Cisplatin 5Carboplatin 5Immune Checkpoint Inhibitors 4tislelizumab 3sintilimab 3lenvatinib 3Oxaliplatin 3Fluorouracil 3Capecitabine 3Bevacizumab 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Gemcitabine 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1toripalimab 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × Sirolimus × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡